TCRA Deal

The TCRA funding plan rests on three assumptions.

The first assumption is that BIG 4 will decide to adopt DLA and collect up to **$1 trillion** of royalty cash flow for TCRA.
The second assumption is that BIG4 will announce their plans for deploying DLA worldwide.

The third assumption: is that post-announcements TCRA's company value will be **$300 billion**.

Extensive review of data and careful reasoning indicates that these three assumptions are valid. No one has shown any of the assumptions are impossible. Hard questioning of the assumptions is essential but it has to be done in another discussion. This paper deals only with the high finance aspects of TCRA under the premise that the assumptions are valid.

This huge TCRA deal is bold and but entirely doable in the hands of certain big players. There are many Wall Street titans who would jump on this deal if they knew about it. Huge benefits for all parties – **win-win-win-win-win** for everyone involved. And it is the **140,000** Rh babies only shot.

The question is not whether TCRA is feasible or not feasible but whether it is possible.

A **Payday Signing Conference** is planned where all parties will sign a contract based on a term sheet negotiated ahead of time. Once everyone signs the contract at the same conference all measures ordained in the contract will be enacted automatically.

- Big 4 DLA announcements already drafted will go out
- TCRA share blocks will be transferred to all parties
- Limited partners will use already raised and committed funds to purchase TCRA share lots and complete payments.

TCRA shares have low value until the contract is signed. Post-announcements, TCRA company value will skyrocket to **~$300 billion** overnight, once the Big 4 announcements make investors confident of the huge royalty cash flow. Limited partners have funds ready and will buy TCRA share lots from all parties at the IDSC.

The term sheet: TCI will transfer blocks of TCRA shares to The Big 4, the underwriters, the VC firm, Rh club members and the foundations.

Our underwriter companies, a top bank, VC and PE firms, will have established a secondary private asset fund(s) with limited partners committed to invest **~$20 billion** to buy TCRA shares at ~**$100 billion** TCRA company value.

At the signing all TCRA shareholders will sell some TCRA shares to limited partner funds. WIRhE will raise **$10 billion**, Foundations **$1 billion**, Underwriter Companies **$1 billion**, **Venture Capital $1 billion,** Big 4 **$4 billion**, Rh Club **$1 billion**, TCI **$3 billion**.

Notes

WIRhE
A **$10 billion** endowment for WIRhE immediately (a **$60 billion** endowment for GAVI will come later)

Foundations
The roles of Rockefeller and Gates will be to see that all the relevant parties are aware of all details of the TCRA deal, particularly making sure all parties are aware that TCRA is the only hope for the **140,000** Rh babies.

Underwriter Company(s)
Will see to it that a general partner and limited partners have assembled the **$20 billion** fund. They will manage the share allotments and sales.

Big 4
The Big 4 will sell shares to LPs to fully fund DLA introduction joining the post announcement TCRA share sales program to sell TCRA shares to realize **$1 billion** each to cover DLA expenses upfront.

Venture Capital
VC(s) will earn shares by recruiting Rh club members. Assist them in TCRA share sales post announcements. Will find investors for future rounds.

RhClub
Billionaires will be allocated **$1 billion** TCRA shares at the signing if they have influenced Big 4. If they donate **$10 million** to WIRhE immediately.

TCI

TCI will sell enough shares to LPs to raise **$3 billion**.

Issues

Necessary realization: The scale of TCRA is truly enormous, as big as Spacex - **$1 trillion profit before taxes over 20 years for TCRA shareholders**. We are talking about net profits of a whole industry, not just one big company.

Will people understand TCRA is the only shot for saving the **140,000** Rh babies dying every year? What are the odds WIRhE can be funded **$250 million** annually sustainably with regular philanthropy?

The main issue is **our lack of access to A-list people**. We must preserve the current working relationships we have with Kevin, Raj and James, who do have access to Rh Club members and develop new relationships.

How do we resolve the catch 22? Big 4 won't sign on to and announce DLA until **$20 billion** LP funds are ready and committed and GPs sign contract. The funds won't buy TCRA shares until Big 4 announce DLA.

Is it a good idea to split the **$500 billion** between Rockefeller and Gates?

TCRA requires all parties to see the whole picture

How much return will the LP investors feel comfortable with at the signing when they accept **all the risk** of the first **$20 billion** investment.

The Pitch

TCRA has identified the enormous clinical lab revenue stream of **$8.8 trillion** that can generate the payment of royalties to TCRA of **$1 trillion** profit before taxes over the next **20** years. This royalty cash flow has a present value, PV, of **$300 billion**. Luckily TCRA owns the perfect IP for the next generation of automated analyzers. Luckily a **powerful oligopoly** of four major companies, *Siemens, Roche, Abbott, and Danaher,* control the global clinical lab market and it's well within their power to use TCRA intellectual property in their next DLA line of equipment and impose **$1 trillion** royalties on global clinical labs over **20** years. Owning **28%** of TCRA Big 4 will accrue **$280 billion** in royalties, all new **profit before taxes** that will double their stock prices immediately on their DLA announcements.

Though royalties on intellectual property by equipment manufacturers are normal in many industries, a royalty model paid by clinical labs has never been used before. Applying royalties to clinical test data revenue is feasible today for the first time because of the existence of TCRA's patent portfolio, supported by the legal forces of the big companies. Global clinical labs will pay royalties for using TCRA'S new patented Dark Lab Automation technology. DLA will make clinical labs much more efficient, with **80%** savings in inlab labor costs. The patents that TCRA happens to own will create an extraordinary return for all TCRA shareholders.

This revenue stream identified by TCRA will be earned by the huge **$240 billion** global clinical lab industry. These are the most assured revenues of any industry because **70%** of actionable medical care decisions are now based on clinical lab test results, which are absolutely fundamental in healthcare today. The **$1 trillion** royalties, net profit before taxes, paid by clinical labs to TCRA shareholders will be earned on the US and International patent portfolio that TCRA owns covering advanced dark clinical lab automation (DLA) technology that the BIG 4 will install in their client clinical labs worldwide.